Critical Comparison: Arrayit (OTCMKTS:ARYC) vs. PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and Arrayit (OTCMKTS:ARYC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for PROCEPT BioRobotics and Arrayit, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	4	8	0	2.43
Arrayit	0	0	0	0	0.00

PROCEPT BioRobotics currently has a consensus price target of $41.45, suggesting a potential upside of 43.29%. Given PROCEPT BioRobotics’ stronger consensus rating and higher probable upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Arrayit.

Valuation & Earnings

This table compares PROCEPT BioRobotics and Arrayit”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	5.35	-$95.57 million	($1.82)	-15.90
Arrayit	N/A	N/A	N/A	N/A	N/A

Arrayit has lower revenue, but higher earnings than PROCEPT BioRobotics.

Profitability

This table compares PROCEPT BioRobotics and Arrayit’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Arrayit	N/A	N/A	N/A

Risk & Volatility

PROCEPT BioRobotics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Arrayit has a beta of -0.22, suggesting that its share price is 122% less volatile than the S&P 500.

Insider and Institutional Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 58.0% of Arrayit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

PROCEPT BioRobotics beats Arrayit on 6 of the 10 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Arrayit

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.